U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07122531) titled 'Recovery With Exogenous Ketones and Antipsychotics' on Aug. 05.
Brief Summary: The RECAP project will evaluate the clinical and metabolic effects of adding exogenous ketones to antipsychotic (AP) treatment in young adults with a first episode of psychosis (FEP).
FEP requires early intervention to limit relapse, chronic symptoms, cognitive decline, and reduced life expectancy. Symptoms include positive (hallucinations, delusions), negative (amotivation, anhedonia), cognitive (attention, working memory), and mood disturbances. Standard care combines second- or third-generation APs with psychosocial interventions. However, many patien...